Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management. Proceedings from a symposium at the 2008 Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting

Support Care Cancer. 2010 Mar:18 Suppl 1:S1-10. doi: 10.1007/s00520-009-0807-z. Epub 2010 Jan 19.

Abstract

Introduction: Chemotherapy-induced nausea and vomiting remains a significant problem for cancer patients.

Discussion: Patient factors such as polypharmacy, medication costs, mucositis, and depression may hinder good antiemetic control, while high workloads, poor communication, and underestimation of the problem on the part of healthcare professionals also play a role. Improving outcomes requires accurate assessment of risk factors, use of guidelines, and better adherence to antiemetic regimens.

Conclusion: Extended-release formulations and new delivery systems such as transdermal patches, nasal sprays, and pumps provide a new strategy that may improve patient outcomes.

Publication types

  • Congress
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiemetics / adverse effects
  • Antiemetics / therapeutic use*
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Humans
  • Nausea / chemically induced*
  • Nausea / drug therapy*
  • Neoplasms / drug therapy*
  • Risk Factors
  • Vomiting / chemically induced*
  • Vomiting / drug therapy*

Substances

  • Antiemetics
  • Antineoplastic Agents